NCT05863273View on ClinicalTrials.gov

Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）

CompletedOBSERVATIONAL

Enrollment

360

Participants

Timeline

Start Date

May 22, 2023

Primary Completion Date

February 10, 2025

Study Completion Date

March 10, 2025

Conditions

Psoriasis

Interventions

DRUG

Apremilast

Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification.

Trial Locations (2)

110001

the First Hospital of China Medical University, Shenyang

Unknown

China-Japan Friendship Hospital, Beijing

All Listed Sponsors

collaborator

China-Japan Friendship Hospital

OTHER

lead

First Hospital of China Medical University

OTHER

NCT05863273 - Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT） | Biotech Hunter | Biotech Hunter